News
News Center
Good News: Jiuzhitang Honored with Multiple Rankings at the 2nd China Traditional Chinese Medicine Brand Building Conference!
2020-12-22
2020 was a year of global pandemic response, as well as a pivotal period for summarizing the achievements of the 13th Five-Year Plan and laying the groundwork for the 14th Five-Year Plan. While the traditional Chinese medicine (TCM) industry actively joined the fight against COVID-19 and achieved significant breakthroughs, it now faces formidable challenges in navigating the new post-pandemic normal. To reflect on the lessons learned from the epidemic response, bolster industry confidence, explore future development strategies, and strengthen the association's service capabilities, the China Association of Traditional Chinese Medicine convened the Second China TCM Brand Building Conference, along with the 5th Council Meeting of the 4th Session, on December 18 and 19, 2020, in Beijing. The event also included meetings of the Standing Council and branch organizations, as well as the inaugural President’s Forum and an exhibition showcasing outstanding TCM brands and their achievements.
The theme of this conference is: Recognizing achievements in the industry's fight against the pandemic, promoting the spirit of traditional Chinese medicine, sharing insights from industrial development experiences, and continuously strengthening Chinese medicinal brands. The event will feature a series of activities centered on the growth of the Chinese medicine industry, including policy briefings, high-level keynote speeches, special recognition ceremonies, brand research initiatives, information dissemination, and project launches—all aimed at driving high-quality development within the sector. Additionally, the conference will include an exhibition platform to showcase and promote leading brand companies and their flagship products, highlighting cutting-edge innovations, technologies, and breakthroughs, while providing valuable services to well-established industry leaders and core members of key industry associations.
Huang Luqi, an academician of the Chinese Academy of Engineering, President of the China Academy of Chinese Medical Sciences, and Chairman of the China Association of Traditional Chinese Medicine, attended the meeting along with over 300 leaders from various branches of the China Association of Traditional Chinese Medicine, representatives from vice-chairman units, council members, and member organizations. Representatives from pharmaceutical companies specializing in traditional Chinese medicine across the country, as well as media reporters, also attended the event. Li Zhenguo, President of Jiuzhitang Group, participated in the meeting and delivered a speech.
(Photo: Huang Luqi, Academician of the Chinese Academy of Engineering, President of the China Academy of Chinese Medical Sciences, and President of the China Association of Traditional Chinese Medicine, delivers a speech.)
Li Zhenguo, President of Jiuzhitang Group, delivered a speech at the China Association of Traditional Chinese Medicine Leaders Forum, where he emphasized that in the post-pandemic era, TCM must seize this historic opportunity to establish an evaluation system uniquely tailored to its strengths—and ultimately go global!
Jiuzhitang, leveraging its absolute brand advantage, has proudly ranked among… "2020 List of Time-Honored Chinese Medicine Brand Leaders" 、 "Top 10 Traditional Chinese Medicine Enterprises" Two major rankings. Meanwhile, Jiuzhitang’s two star products—Shuxuetong Injection and Liuwei Dihuang Wan, both exceeding 100 million yuan in sales—have made it onto the lists. "List of Clinically Valuable Traditional Chinese Medicine Brands"!
The Shuxuetong Injection and Liuwei Dihuang Wan were selected for the "Clinical Value of Traditional Chinese Medicine Brands Ranking," an initiative aimed at highlighting the clinical efficacy of TCM formulations, enhancing brand visibility, and driving high-quality growth in the Chinese herbal medicine industry. Built on the research outcomes of two key projects—the "Brand Value Enhancement Project for Traditional Chinese Medicine and Biopharmaceuticals," initiated by the former State Administration for Market Regulation, and the standardized project "Clinical Practice Guidelines for TCM Formulations Targeting Key Disease Areas"—the ranking focuses on TCM’s core therapeutic areas, prioritizing two major categories: TCM formulations and time-tested, renowned classic prescriptions. Through a rigorous process involving enterprise product submissions, extensive literature reviews, and proactive research conducted by a panel of brand experts, the selection criteria were carefully defined. Ultimately, based on the Chinese Herbal Medicine Brand Evaluation Group Standards and procedures issued by the China Association for Traditional Chinese Medicine, the 2020 Clinical Value Ranking of TCM Brands was unveiled.
Notably, at the meeting, Director Sun Xiaobo from the Institute of Scientific Plant Medicine at China Medical College introduced to the attendees how traditional Chinese medicine can undergo re-evaluation and evidence-based medical research—guided by clinical needs and value—using "Shuxuetong Injection," one of Jiuzhitang's flagship products worth over 100 million yuan, as a prime example. Director Sun emphasized that According to a meta-analysis, Shuxuetong demonstrates significant clinical efficacy in the treatment of acute ischemic stroke.
"Shuxuetong Injection" is the first domestically developed animal-based compound traditional Chinese medicine injection, independently researched and formulated by Mr. Li Zhenguo, President of Jiuzhitang Group. It holds 1 PCT patent (Patent Application No.: PCT/2007/070190) and has been granted 16 invention patents—14 of which are national-level inventions, with two being utility models. As China's first Class 2 new drug (National Drug Approval Number: Z20010100), Shuxuetong is uniquely formulated using a combination of leeches and earthworms, with active ingredients repeatedly extracted through freeze-thaw cycles. This innovative approach successfully addresses the challenge of allergic reactions to foreign proteins in animal-based compound injections, filling a significant gap both domestically and internationally in this therapeutic area while simultaneously driving breakthroughs in traditional Chinese medicine innovation. Most importantly, Shuxuetong has saved countless lives of stroke patients. It features the following characteristics:
Multi-target action effectively inhibits thrombus formation.
Promote the opening of collateral circulation and revascularization, enhancing blood supply to the brain.
Effectively reduces disability and recurrence rates in patients with ischemic stroke, while improving quality of life.
Combining antiplatelet drugs leads to better efficacy without increasing the risk of bleeding.
The incidence of adverse reactions is low, at only 1.97‰.
Also making the "Clinical Value of Traditional Chinese Medicine Brand List" at this year's conference—alongside Shuxuetong Injection—are Jiuzhitang’s Liuwei Dihuang Wan, a time-honored remedy rooted in the ancient formula created by Qian Yi during the Northern Song Dynasty. Leveraging cutting-edge domestic technology for concentrated pill production, these pills are perfectly shaped, uniformly sized, and proudly earn the nickname "Black Pearl." Known for their nourishing and kidney-tonifying properties, they are specifically prescribed to address symptoms such as kidney-yin deficiency, dizziness, tinnitus, and weakness in the lower back and knees. With annual sales exceeding 30 million bottles, the product ranks among the top three in terms of national retail volume within its category.
Meanwhile, during the conference, Jiuzhitang Group organized its subsidiaries—Jiuzhitang Medical Health Industry Development (Beijing) Co., Ltd., Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd., the OTC Division, and the Prescription Drug Business Team—to jointly exhibit at the event. Together, they showcased Jiuzhitang Group's comprehensive range of product lines, as well as the company's innovative strategies in traditional Chinese medicine, biopharmaceuticals, stem cell technology, and internet-based healthcare platforms—gaining widespread attention from attendees across various sectors.
(Photo: Li Zhenguo, President of Jiuzhitang Group, poses for a group photo with representatives from participating member units)
(Photo: Liu Chunfeng, Vice President of Jiuzhitang Group, introduces the company's overall industrial layout to Liu Zhanglin, President of the China Association of Traditional Chinese Medicine.)
In recent years, guided by the guiding principles outlined in General Secretary Xi Jinping’s series of important speeches, and with the high attention and robust support from the CPC Central Committee and the State Council, China’s traditional Chinese medicine industry has experienced rapid growth and is now riding a strong momentum for development! As we enter a new stage of development, Jiuzhitang—a leading modern pharmaceutical enterprise entrusted with both historical responsibility and industry-leading influence—will continue to earnestly implement General Secretary Xi Jinping’s visionary “three transformative shifts”: from “Made in China” to “Created in China,” from “China Speed” to “China Quality,” and from “Chinese Products” to “Chinese Brands.” These shifts are crucial for driving profound transformations in economic quality, efficiency, and innovation, thereby fostering the high-quality growth of the TCM sector. By upholding the essence of tradition while embracing innovation, Jiuzhitang will integrate its corporate strategy of "innovation through inheritance and growth through innovation" into national strategies and initiatives, leveraging its groundbreaking achievements to bolster China’s global brand presence. Staying true to our original aspirations, we remain committed to scaling up and strengthening our company, ensuring that Chinese brands earn the respect they deserve on the world stage—and moving forward with unwavering determination!
Previous:
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy